Management of Osteoporosis
Key Points
Key Points
Clinicians are advised to assess fracture risk using established tools.
- For those with substantial risk of osteoporotic fracture the clinician should obtain a bone mineral density.
The bone health of all patients may benefit from optimizing nutrition, exercise and lifestyle.
When a pharmacologic agent is indicated, bisphosphonates or denosumab, at osteoporosis-indicated dosages, are the preferred interventions.
Assessment
...ssessme...
Ris...
...ndation 1.1. It is recommended that patient...
....2. Clinicians should be aware tha...
...ommendation 1.3. Clinicians may use a risk ass...
Screening
...endation 2.1. Patients with non-metastatic cancer...
...on 2.2. Patients with non-metastatic ca...
Treatment
Treatmen...
...harmacological Intervention...
...ndation 3.1. Clinicians should encourage patie...
...ation 3.2. Clinicians should actively e...
...n 3.3. Clinicians should actively...
...ogical Intervention...
...n 3.4. For patients with non-metas...
...ommendation 3.5. Provided T-score and/or risk...
...Algorithm for Maintaining Bone Health in Individ...
...porotic Fracture Risk FactorsHavin...
...e Loss Associated with Various Cancer The...
...ommonly used Bone Modifying Agents for the Pr...
...le 4. Estimated Drug Costs for Bone Modifyin...